Avantor's second quarter 2025 performance showed a slight decrease in net sales, reaching $1.68 billion, though organic revenue remained flat. Net income fell to $64.7 million, and adjusted EPS was $0.24. The Laboratory Solutions segment experienced a reported decrease in sales, while Bioscience Production saw an increase. The company generated strong operating cash flow of $154.4 million and free cash flow of $125.4 million.
Net sales for Q2 2025 were $1.68 billion, a 1% decrease year-over-year, with organic revenue remaining flat.
Net income for the quarter was $64.7 million, a decrease from $92.9 million in Q2 2024, and adjusted net income was $161.2 million.
Diluted GAAP EPS was $0.09, and adjusted EPS was $0.24.
Operating cash flow stood at $154.4 million, and free cash flow was $125.4 million.
The report does not contain specific forward-looking guidance for the upcoming quarter or fiscal year. It primarily focuses on past performance and strategic positioning.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance